New inhaled drug shows promise for easing lung pressure in rare Heart-Lung condition

NCT ID NCT05343637

Completed Symptom relief Sponsor: Respira Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an inhaled medication called RT234 in 14 adults with pulmonary arterial hypertension (PAH), a condition where blood pressure in the lungs is dangerously high. The goal was to see if the drug could quickly lower lung blood pressure during a heart catheterization procedure. The study also checked for side effects like headache or cough. This is an early-phase trial to gather safety and effectiveness data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Familial Primary Pulmonary Hypertension lung disorder pulmonary arterial hypertension pulmonary hypertension respiratory system disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Show contact details

Locations

Royal Hobart Hospital

Hobart, Tasmania, 7000, Australia
St Vincent's Hospital

Darlinghurst, New South Wales, 2010, Australia
The Alfred Hospital

Melbourne, Victoria, 3004, Australia